1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of... 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include those in B-cell and T-cell lymphomas.
- Mechanism
- Curator reviewed
1D09C3 binds specifically to the MHC (major histocompatibility complex) class II molecule, which is found mainly on the surface of blood cells and certain tumor cells. It selectively kills activated, proliferating MHC class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to kill these tumor cells by inducing programmed cell death.
- Primary indication
- Intended for the treatment of various forms of cancer.Curator reviewed
- Code names
- 1D09C3
Resolves to
What you can answer from here — as of April 02, 2025
Which companies are running trials of 1D09C3, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account